Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function

International Journal of Cancer

Volumn 130, Issue 3, 2012, Pages 677-684

  Maita, Shinya ^a   Yuasa, Takeshi ^a,b   Tsuchiya, Norihiko ^a   Mitobe, Yoko ^a   Narita, Shintaro ^a   Horikawa, Yohei ^a   Hatake, Kiyohiko ^b   Fukui, Iwao ^b   Kimura, Shinya ^c   Maekawa, Taira ^d   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

bone metastases; in vivo imaging system; renal cell carcinoma; sunitinib

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; SUNITINIB;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; OSTEOCLASTS; PEPTIDES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82255162986     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26034     Document Type: Article

References (30)

1. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. (Pubitemid 46630489)
2. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Pérol D, Lasset C,. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13: 1460-68.
3. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2009; 3.
4. Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K,. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 2007; 52: 163-8.
5. Kuczyk MA, Anastasiadis AG, Zimmermann R, Merseburger AS, Corvin S, Stenzl A,. Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer. BJU Int 2005; 96: 721-7; quiz i-ii. (Pubitemid 41391417)
6. Oudard S, George D, Medioni J, Motzer R,. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 2007; 18 (Suppl 10): x25-x31.
7. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ,. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-96.
8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35. (Pubitemid 46630490)
9. Motzer RJ, Hoosen S, Bello CL, Christensen JG,. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Exp Opin Invest Drugs 2006; 15: 553-61.
10. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK,. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-66. (Pubitemid 38019277)
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
12. Yuasa T, Nogawa M, Kimura S, Yokota A, Sato K, Segawa H, Kuroda J, Maekawa T,. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res 2005; 11: 853-9. (Pubitemid 40116914)
13. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A, Maekawa T,. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 2005; 217: 243-53. (Pubitemid 40023124)
14. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA,. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 2007; 18: 681-5. (Pubitemid 46525540)
15. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37. (Pubitemid 36109749)
16. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP,. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27: 391-9.
17. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T,. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 2007; 14: 2126-35. (Pubitemid 47578153)
18. Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy DR, Dudek AZ,. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 2008; 44: 2506-17.
19. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE,. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
20. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R,. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35. (Pubitemid 46223998)
21. Ruzicka FJ, Schmid SM, Groveman DS, Cummings KB, Borden EC,. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. Cancer Res 1987; 47: 4582-9. (Pubitemid 17124634)
22. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B,. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-31.
23. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63.
24. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73. (Pubitemid 27198158)
25. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-10.
26. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007; 13 (2 Part 2): 671-9.
27. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM,. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61. (Pubitemid 38340304)
28. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-53. (Pubitemid 41132743)
29. Ljungberg BJ, Jacobsen J, Rudolfsson SH, Lindh G, Grankvist K, Rasmuson T,. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int 2006; 98: 661-7. (Pubitemid 44185895)
30. Ebos JM, Lee CR, Christensen JG, Mutsaers J, Kerbel RS,. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-74. (Pubitemid 350210993)